Retatrutide (developmental code LY3437943) is an investigational once-weekly injectable from Eli Lilly. It is a single molecule that activates three metabolic hormone receptors at once — GIP, GLP-1, and glucagon — so it is called a "triple agonist." The GLP-1/GIP arms are thought to curb appetite and improve blood-sugar handling; the added glucagon arm is thought to raise energy expenditure, which is what distinguishes it from drugs already on the market.
NOT FDA-approved and NOT available by prescription — it is still an experimental drug in clinical trials, so no pharmacy, telehealth clinic, or "men's health" site can legally sell real, approved retatrutide because no such approved product exists. WARNING: "retatrutide"/"reta" vials sold online as powders or pre-mixed peptides (often labeled "for research purposes" or "not for human consumption") are unapproved, unregulated grey-market research chemicals with unknown purity, dose, and contents. Do not buy them and do not inject them — there is no sterility guarantee, no quality control, and no one accountable if you are harmed. The legitimate path is a registered clinical trial under medical supervision, not a website. Verified against ClinicalTrials.gov: Lilly runs a Phase 1-3 program including a completed Phase 2 (NCT04881760), Phase 3 TRIUMPH obesity trials, TRIUMPH-Outcomes CV/kidney trial (NCT06383390), and a "pre-approval expanded access" record (NCT07629401) that by definition exists only because the drug is not yet approved.
Grounded in the Phase 2 trial: Jastreboff AM et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial," N Engl J Med 2023;389(6):514-526 (PMID 37366315; NCT04881760; Lilly-funded). Verified exactly against PubMed and the ClinicalTrials.gov API: double-blind, randomized, placebo-controlled, 338 adults with obesity, weekly injection for 48 weeks at 1/4/8/12 mg vs placebo. Least-squares mean body-weight change at 48 weeks was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg highest dose) vs −2.1% placebo. The widely quoted "~24%" is specifically the 12 mg group average, NOT an all-comers average and NOT a guaranteed individual result. Hedges required and present: this is a mid-stage (~11-month, few-hundred-person) trial, weight was still trending down at 48 weeks, it was not powered for rare or long-term safety signals, and Phase 2 results do not always hold at Phase 3 scale. Phase 3 TRIUMPH trials (e.g., NCT05929066, 2,335 participants, listed COMPLETED) exist, but no peer-reviewed Phase 3 efficacy percentage is quoted — treat any Phase 3 number circulating online as unconfirmed until published.
Mechanism comparison is correct: Ozempic = semaglutide, a single-target GLP-1 agonist (approved for type 2 diabetes; same molecule at higher dose is Wegovy for weight). Tirzepatide (Mounjaro/Zepbound) is a dual GIP+GLP-1 agonist. Retatrutide is a triple GIP+GLP-1+glucagon agonist. On paper retatrutide's top-line Phase 2 result (~−24% at 48 weeks, highest dose) looks larger than commonly cited figures for semaglutide 2.4 mg (~15% at 68 weeks) and tirzepatide (~20-21% at 72 weeks) — but these are CROSS-TRIAL comparisons with different participants, durations, doses, and designs, NOT head-to-head. You cannot conclude "retatrutide beats Ozempic by X%." Lilly is running actual head-to-head studies (reta vs tirzepatide NCT06662383; reta vs semaglutide NCT06260722, both verified on ClinicalTrials.gov), and those results — not cross-trial math — will settle it. Also: two of the three drugs are FDA-approved and prescribable today; retatrutide is not.
In the Phase 2 trial the most common side effects were gastrointestinal (nausea, vomiting, diarrhea, constipation) — dose-related, mostly mild-to-moderate, and reduced by starting low and titrating up, the same tolerability pattern as other GLP-1-class drugs. Dose-dependent heart-rate increases peaked around 24 weeks then declined, and because the glucagon component affects glucose/metabolic parameters, labs are monitored closely. Long-term safety is UNKNOWN: Phase 2 was only 48 weeks in a few hundred people, so rare adverse events, multi-year effects, effects in people with other conditions, and post-discontinuation weight regain are all still being studied. This uncertainty is exactly why it is not yet approved and why self-experimenting with grey-market "reta" — unproven drug, unverified dose, unverified source, no medical monitoring — is reckless.
Retatrutide is a genuinely promising experimental obesity drug with among the strongest early (Phase 2) weight-loss data reported, but it is NOT FDA-approved, NOT available by prescription, and its full Phase 3 safety/efficacy picture is not settled. Any "retatrutide/reta" peptide sold online is an unapproved, unregulated research chemical — do not buy or inject it. Anyone wanting effective, supervised weight-loss treatment now should talk to a licensed clinician about actually-approved options (semaglutide, tirzepatide); anyone specifically interested in retatrutide should look to a registered clinical trial. General information, not medical advice.
General information, not medical advice. Retatrutide is an investigational drug not approved by the FDA and not available by prescription; trial figures are averages that may change as studies complete. Products sold online as “retatrutide” or research peptides are unapproved and unsafe — do not use them.